Comparative Pharmacology
Head-to-head clinical analysis: ETHINYL ESTRADIOL ETONOGESTREL versus NORLUTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHINYL ESTRADIOL ETONOGESTREL versus NORLUTIN.
ETHINYL ESTRADIOL; ETONOGESTREL vs NORLUTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ETHINYL ESTRADIOL is an estrogen; ETONOGESTREL is a progestin. The combination suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, thickening cervical mucus to impede sperm penetration, and altering endometrial receptivity.
Synthetic progestin that binds to progesterone receptors, suppressing gonadotropin secretion and altering endometrial lining.
One vaginal ring (0.120 mg etonogestrel/0.015 mg ethinyl estradiol per day) inserted vaginally and left in place for 3 weeks, followed by a 1-week ring-free period.
5 mg orally three times daily for endometriosis; 5 mg orally daily from day 5 to day 25 of menstrual cycle for amenorrhea.
None Documented
None Documented
Ethinyl estradiol: ~13 hours (range 7-20 h); etonogestrel: ~25 hours (range 15-36 h). At steady state, elimination half-life extends to 20-30 h for etonogestrel.
Terminal elimination half-life: 5–14 hours (mean ~8 hours). Clinical context: short half-life necessitates daily dosing for contraceptive efficacy.
Urine (60-70% as metabolites, <10% unchanged), feces (20-30% via biliary elimination).
Mainly renal as glucuronide and sulfate conjugates; approximately 70% renal, 30% fecal/biliary.
Category D/X
Category C
Progestin
Progestin